These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

533 related articles for article (PubMed ID: 9537794)

  • 1. Ophthalmic drug delivery systems--recent advances.
    Bourlais CL; Acar L; Zia H; Sado PA; Needham T; Leverge R
    Prog Retin Eye Res; 1998 Jan; 17(1):33-58. PubMed ID: 9537794
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Ocular preparations: the formulation approach.
    Kaur IP; Kanwar M
    Drug Dev Ind Pharm; 2002 May; 28(5):473-93. PubMed ID: 12098838
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Recent advances in ocular drug delivery.
    Achouri D; Alhanout K; Piccerelle P; Andrieu V
    Drug Dev Ind Pharm; 2013 Nov; 39(11):1599-617. PubMed ID: 23153114
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparison of thermosensitive in situ gels and drug-resin complex for ocular drug delivery: In vitro drug release and in vivo tissue distribution.
    Wei Y; Li C; Zhu Q; Zhang X; Guan J; Mao S
    Int J Pharm; 2020 Mar; 578():119184. PubMed ID: 32112932
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Improvements in Topical Ocular Drug Delivery Systems: Hydrogels and Contact Lenses.
    Ribeiro AM; Figueiras A; Veiga F
    J Pharm Pharm Sci; 2015; 18(5):683-95. PubMed ID: 26670365
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Ophthalmic drug dosage forms: characterisation and research methods.
    Baranowski P; Karolewicz B; Gajda M; Pluta J
    ScientificWorldJournal; 2014; 2014():861904. PubMed ID: 24772038
    [TBL] [Abstract][Full Text] [Related]  

  • 7. New directions in the optimization of ocular drug delivery.
    Lee VH
    J Ocul Pharmacol; 1990; 6(2):157-64. PubMed ID: 2203851
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Sustained ocular delivery of brimonidine tartrate using ion activated in situ gelling system.
    Geethalakshmi A; Karki R; Jha SK; Venkatesh DP; Nikunj B
    Curr Drug Deliv; 2012 Mar; 9(2):197-204. PubMed ID: 22283647
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Ocular disposition, pharmacokinetics, efficacy and safety of nanoparticle-formulated ophthalmic drugs.
    Bu HZ; Gukasyan HJ; Goulet L; Lou XJ; Xiang C; Koudriakova T
    Curr Drug Metab; 2007 Feb; 8(2):91-107. PubMed ID: 17305490
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Colloidal carriers for ophthalmic drug delivery.
    Mainardes RM; Urban MC; Cinto PO; Khalil NM; Chaud MV; Evangelista RC; Gremiao MP
    Curr Drug Targets; 2005 May; 6(3):363-71. PubMed ID: 15857294
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Optimizing ophthalmic delivery of a poorly water soluble drug from an aqueous in situ gelling system.
    Senjoti FG; Timmins P; Conway BR; Smith AM
    Eur J Pharm Biopharm; 2020 Sep; 154():1-7. PubMed ID: 32599271
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Terminalia arjuna gum/alginate in situ gel system with prolonged retention time for ophthalmic drug delivery.
    Noreen S; Ghumman SA; Batool F; Ijaz B; Basharat M; Noureen S; Kausar T; Iqbal S
    Int J Biol Macromol; 2020 Jun; 152():1056-1067. PubMed ID: 31751751
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Polymer-based carriers for ophthalmic drug delivery.
    Imperiale JC; Acosta GB; Sosnik A
    J Control Release; 2018 Sep; 285():106-141. PubMed ID: 29964135
    [TBL] [Abstract][Full Text] [Related]  

  • 14. In vitro and in vivo evaluation of in situ gelling systems for sustained topical ophthalmic delivery: state of the art and beyond.
    Destruel PL; Zeng N; Maury M; Mignet N; Boudy V
    Drug Discov Today; 2017 Apr; 22(4):638-651. PubMed ID: 28017837
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Polymeric nanoparticulate system: a potential approach for ocular drug delivery.
    Nagarwal RC; Kant S; Singh PN; Maiti P; Pandit JK
    J Control Release; 2009 May; 136(1):2-13. PubMed ID: 19331856
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Mechanistic modeling of ophthalmic drug delivery to the anterior chamber by eye drops and contact lenses.
    Gause S; Hsu KH; Shafor C; Dixon P; Powell KC; Chauhan A
    Adv Colloid Interface Sci; 2016 Jul; 233():139-154. PubMed ID: 26318359
    [TBL] [Abstract][Full Text] [Related]  

  • 17. In situ gel systems as 'smart' carriers for sustained ocular drug delivery.
    Agrawal AK; Das M; Jain S
    Expert Opin Drug Deliv; 2012 Apr; 9(4):383-402. PubMed ID: 22432690
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Drug delivery to the anterior segment of the eye: A review of current and future treatment strategies.
    Mofidfar M; Abdi B; Ahadian S; Mostafavi E; Desai TA; Abbasi F; Sun Y; Manche EE; Ta CN; Flowers CW
    Int J Pharm; 2021 Sep; 607():120924. PubMed ID: 34324989
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Applications of poloxamers in ophthalmic pharmaceutical formulations: an overview.
    Almeida H; Amaral MH; Lobão P; Sousa Lobo JM
    Expert Opin Drug Deliv; 2013 Sep; 10(9):1223-37. PubMed ID: 23688342
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Topical Advances in Mucoadhesive Ocular Drug Delivery System.
    Billowria K; Sandhu NK; Singh B
    Curr Drug Deliv; 2023; 20(8):1127-1140. PubMed ID: 36221885
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 27.